What is the 21st Century Cures Act of 2016, and what did it aim to accelerate?

What is the 21st Century Cures Act of 2016, and what did it aim to accelerate?

• A. Decreases funding for NIH and slows drug approvals.
• B. Focuses only on mental health parity.
• C. Accelerates medical product development and research; funds NIH and modernizes regulatory pathways.
• D. Creates a new federal bioethics board.

Answer: (C)

The main idea being tested is understanding what the 21st Century Cures Act was designed to do. This law aimed to speed up the process of bringing new medical products to patients by accelerating medical product development and research and by updating the regulatory system that oversees these products. It accomplishes this by providing funding to the National Institutes of Health and by modernizing the FDA’s regulatory pathways, so reviews and approvals can happen faster while still prioritizing safety. The act also supports modern approaches to clinical trials, precision medicine, and digital health, all intended to get effective therapies to people more quickly. This is why the correct choice fits best: it captures both the push to accelerate development and the commitment to strengthen funding for NIH and modernization of regulatory processes at FDA. The other options miss the mark because the act did not reduce funding to NIH, it did not focus solely on mental health parity, and it did not establish a new federal bioethics board.

The main idea being tested is understanding what the 21st Century Cures Act was designed to do. This law aimed to speed up the process of bringing new medical products to patients by accelerating medical product development and research and by updating the regulatory system that oversees these products. It accomplishes this by providing funding to the National Institutes of Health and by modernizing the FDA’s regulatory pathways, so reviews and approvals can happen faster while still prioritizing safety. The act also supports modern approaches to clinical trials, precision medicine, and digital health, all intended to get effective therapies to people more quickly.

This is why the correct choice fits best: it captures both the push to accelerate development and the commitment to strengthen funding for NIH and modernization of regulatory processes at FDA. The other options miss the mark because the act did not reduce funding to NIH, it did not focus solely on mental health parity, and it did not establish a new federal bioethics board.